Elevar-Hengrui hit with third FDA rejection for liver cancer therapy over manufacturing concerns
July 10 (Reuters) – Elevar Therapeutics and Hengrui suffered a fresh setback on Friday after the U.S. FDA declined to approve their drug combination for a type of liver cancer, citing deficiencies at a manufacturing site. The setback marks the FDA’s …